625
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Berberine-Loaded Targeted Nanoparticles as Specific Helicobacter Pylori Eradication Therapy: In Vitro and In Vivo Study

, , , , , & show all
Pages 57-71 | Published online: 01 Sep 2014

References

  • Beil W , KilianP . EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells . Phytomedicine14 ( 6 ), 5 – 8 ( 2007 ).
  • Graham DY . Campylobacter pylori and peptic ulcer disease . Gastroenterology96 ( 2 ), 615 – 625 ( 1989 ).
  • Hazell SL , LeeA , BradyL , HennessyW . Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium . J. Infect. Dis.153 ( 4 ), 658 – 663 ( 1986 ).
  • Fedwick JP , LapointeTK , MeddingsJB , ShermanPM , BuretAG . Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability . Infect. Immun.73 ( 12 ), 7844 – 7852 ( 2005 ).
  • Falk P , RothKA , BorénT , WestblomTU , GordonJI , NormarkS . An in vitro adherence assay reveals that Helicobacter pylori exhibits cell lineage-specific tropism in the human gastric epithelium . Proc. Natl Acad. Sci. USA90 ( 5 ), 2035 – 2039 ( 1993 ).
  • Lin YH , TsaiSC , LaiCH , LeeCH , HeZS , TsengGC . Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori . Biomaterials34 ( 18 ), 4466 – 4479 ( 2013 ).
  • Özden A , SevenG , BektaşM . Effectiveness of different treatment regimens in Helicobacter pylori eradication: ten-year experience of a single institution . Turk. J. Gastroenterol.21 ( 3 ), 218 – 223 ( 2010 ).
  • Rangari VK , MohammadGM , JeelaniSet al. Synthesis of Ag/CNT hybrid nanoparticles and fabrication of their nylon-6 polymer nanocomposite fibers for antimicrobial applications . Nanotechnology21 ( 9 ), 095102 ( 2010 ).
  • Guo CY , WuYB , LiuHL , WuJY , ZhongMZ . Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection . World J. Gastroenterol.10 ( 5 ), 747 – 749 ( 2004 ).
  • Koletzko S , RichyF , BontemsPet al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe . Gut55 ( 12 ), 1711 – 1716 ( 2006 ).
  • de Bortoli N , LeonardiG , CianciaEet al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics . Am. J. Gastroenterol.102 ( 5 ), 951 – 956 ( 2007 ).
  • Du P , ZhuS , LüP . Antibacterial activity of 20 kinds of Chinese medicinal materials for Helicobacter pylori in vitro . Zhong Yao Cai.24 ( 3 ), 188 – 189 ( 2001 ).
  • Yang P , SongDQ , LiYHet al. Synthesis and structure–activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators . Bioorg. Med. Chem. Lett.18 ( 16 ), 4675 – 4677 ( 2008 ).
  • Tang J , FengY , TsaoS , WangN , CurtainR , WangY . Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations . J. Ethnopharmacol.126 ( 1 ), 5 – 17 ( 2009 ).
  • Amin AH , SubbaiahTV , AbbasiKM . Berberine sulfate: antimicrobial activity, bioassay, and mode of action . Can. J. Microbiol.15 ( 9 ), 1067 – 1076 ( 1969 ).
  • Chung JG , WuLT , ChangSH , LoHH , HsiehSE . Inhibitory actions of berberine on growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients . Int. J. Toxicol.18 ( 1 ), 35 – 40 ( 1999 ).
  • Mahady GB , PendlandSL , StoiaA , ChadwickLR . In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis . Phytother. Res.17 ( 3 ), 217 – 221 ( 2003 ).
  • Wang YX , ZhengYM . Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine . J. Cardiovasc. Pharmacol.30 ( 2 ), 214 – 222 ( 1997 ).
  • Panyam J , LabhasetwarV . Biodegradable nanoparticles for drug and gene delivery to cells and tissue . Adv. Drug Deliv. Rev.55 ( 3 ), 329 – 347 ( 2003 ).
  • Khan MK , MincLD , NigavekarSSet al. Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy . Nanomedicine4 ( 1 ), 57 – 69 ( 2008 ).
  • Pinto Reis C , NeufeldRJ , RibeiroAJ , VeigaF . Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems . Nanomedicine2 ( 2 ), 53 – 65 ( 2006 ).
  • Chang CH , HuangWY , LaiCHet al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori . Acta Biomater.7 ( 2 ), 593 – 603 ( 2011 ).
  • Becker DJ , LoweJB . Fucose: biosynthesis and biological function in mammals . Glycobiology13 ( 7 ), 41R – 53R ( 2003 ).
  • Mitchell E , HoulesC , SudakevitzDet al. Structural basis for oligosaccharide-mediated adhesion of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients . Nat. Struct. Biol.9 ( 12 ), 918 – 921 ( 2002 ).
  • Loris R , TielkerD , JaegerKE , WynsL . Structural basis of carbohydrate recognition by the lectin LecB from Pseudomonas aeruginosa . J. Mol. Biol.331 ( 4 ), 861 – 870 ( 2003 ).
  • Thanou M , VerhoefJC , JungingerHE . Chitosan and its derivatives as intestinal absorption enhancers . Adv. Drug Deliv. Rev.50 ( 1 ), S91 – S101 ( 2001 ).
  • Mansouri S , CuieY , WinnikFet al. Characterization of folate-chitosan-DNA nanoparticles for gene therapy . Biomaterials27 ( 9 ), 2060 – 2065 ( 2006 ).
  • Sameti M , BohrG , Ravi KumarMNet al. Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery . Int. J. Pharm.266 ( 1–2 ), 51 – 60 ( 2003 ).
  • Elbein AD , PanYT , PastuszakI , CarrollD . New insights on trehalose: a multifunctional molecule . Glycobiology13 ( 4 ), 17R–27R ( 2003 ).
  • Sashiwa H , AibaS . Chemically modified chitin and chitosan as biomaterials . Prog. Polym. Sci.29 ( 9 ), 887 – 908 ( 2004 ).
  • Donati I , StredanskaS , SilvestriniGet al. The aggregation of pig articular chondrocyte and synthesis of extracellular matrix by a lactose-modified chitosan . Biomaterials26 ( 9 ), 987 – 998 ( 2005 ).
  • Wang SD , SongBS , LiK . Determination of berberine in decocted liquid from shenshu granules with water by reversed-phase liquid chromatography . Se Pu.18 ( 3 ), 261 – 262 ( 2000 ).
  • Richards CL , BuchholzBJ , FordTE , BroadawaySC , PyleBH , CamperAK . Optimizing the growth of stressed Helicobacter pylori . J. Microbiol. Methods84 ( 2 ), 174 – 182 ( 2011 ).
  • Lin YH , LinJH , PengSFet al. Multifunctional gentamicin supplementation of poly (γ-glutamic acid)-based hydrogels for wound dressing application . J. Appl. Polym. Sci.120 ( 2 ), 1057 – 1068 ( 2011 ).
  • Huang WY , YehCL , LinJH , YangJS , KoTH , LinYH . Development of fibroblast culture in three-dimensional activated carbon fiber-based scaffold for wound healing . J. Mater. Sci. Mater. Med.23 ( 6 ), 1465 – 1478 ( 2012 ).
  • Lin YH , ChiouSF , LaiCHet al. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication . Process Biochem.47 ( 10 ), 1469 – 1478 ( 2012 ).
  • Sogias IA , WilliamsAC , KhutoryanskiyVV . Why is chitosan mucoadhesive?Biomacromolecules9 ( 7 ), 1837 – 1842 ( 2008 ).
  • Ramesan RM , SharmaCP . Modification of chitosan nanoparticles for improved gene delivery . Nanomedicine (Lond).7 ( 1 ), 5 – 8 ( 2012 ).
  • Madrid JF , LeisO , Díaz-FloresL , SáezFJ , HernándezF . Lectin-gold localization of fucose residues in human gastric mucosa . J. Histochem. Cytochem.46 ( 11 ), 1311 – 1320 ( 1998 ).
  • Moriwaki K , MiyoshiE . Fucosylation and gastrointestinal cancer . World J. Hepatol.2 ( 4 ), 151 – 161 ( 2010 ).
  • Kim YS , KimYW , SiddiquiB , TsaoD . Membrane-associated, fucose-containing glycoproteins and glycolipids of cultured epithelial cells from human colonic adenocarcinoma and fetal intestine . Eur. J. Cancer Clin. Oncol.18 ( 12 ), 1329 – 1336 ( 1982 ).
  • Wen S , MossSF . Helicobacter pylori virulence factors in gastric carcinogenesis . Cancer Lett.282 ( 1 ), 1 – 8 ( 2009 ).
  • Wroblewski LE , PeekRMJr , WilsonKT . Helicobacter pylori and gastric cancer: factors that modulate disease risk . Clin. Microbiol. Rev.23 ( 4 ), 713 – 739 ( 2010 ).
  • Khanvilkar K , DonovanMD , FlanaganDR . Drug transfer through mucus . Adv. Drug Deliv. Rev.48 ( 2–3 ), 173 – 193 ( 2001 ).
  • Lehr CM , BouwstraJA , SchachtEH , JungingerHE . In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers . Int. J. Pharm.78 ( 1–3 ), 43 – 48 ( 1992 ).
  • Miyazaki S , NakayamaA , OdaM , TakadaM , AttwoodD . Chitosan and sodium alginate based bioadhesive tablets for intraoral drug delivery . Biol. Pharm. Bull.17 ( 5 ), 745 – 747 ( 1994 ).
  • Amiji MM . Tetracycline-containing chitosan microspheres for local treatment of Helicobacter pylori infection . Cellulose14 ( 1 ), 3 – 14 ( 2007 ).
  • Yang P , SongDQ , LiYHet al. Synthesis and structure–activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators . Bioorg. Med. Chem. Lett.18 ( 16 ), 4675 – 4677 ( 2008 ).
  • Casu B , GennaroU . A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides . Carbohydr. Res.39 ( 1 ), 168 – 176 ( 1975 ).
  • Li Y , WangHY , ChoCH . Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats . J. Pharmacol. Exp. Ther.290 ( 2 ), 789 – 796 ( 1999 ).
  • Konturek PC , KonturekSJ , BrzozowskiT , ErnstH . Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions . Eur. J. Gastroenterol. Hepatol.7 ( 10 ), 933 – 937 ( 1995 ).
  • Hall AJ , TrippM , HowellT , DarlandG , BlandJS , BabishJG . Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs . Prostaglandins Leukot. Essent. Fatty Acids75 ( 1 ), 9 – 17 ( 2006 ).
  • van der Lubben IM , VerhoefJC , BorchardG , JungingerHE . Chitosan and its derivatives in mucosal drug and vaccine delivery . Eur. J. Pharm. Sci.14 ( 3 ), 201 – 207 ( 2001 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.